Why the study?
Do PCSK9 inhibitors and Lp(a) reduction therapy slow the progression of nonrheumatic aortic stenosis?
Do PCSK9 inhibitors and Lp(a) reduction therapy slow the progression of nonrheumatic aortic stenosis?
Answers are grounded in this paper and cite their sources.
PCSK9 inhibitors and Lp(a) reduction therapy represent a potential disease-modifying pharmacological approach to slow the progression of nonrheumatic aortic stenosis.
The exploratory analysis of FOURIER trial has offered a ray of hope for patients with nonrheumatic aortic stenosis (AS). At present, the only definitive treatment of severe AS is aortic valve replacement (AVR). Despite transaortic valvular replacement revolutionizing the treatment of AS, it still remains a progressive condition, with no disease-modifying pharmacotherapy. Angiotensin-converting-enzyme inhibitors, angiotensin receptor blockers, eplerenone, nitrates and statins all have been tried previously but failed to slow down the progression of aortic stenosis. Recently, there has been an emerging role of lipoprotein A [Lp(a)] in the pathogenesis of AS. This raises the possibility that long-term therapy with specific emphasis on Lp(a) reduction may reduce or slow the progression of AS.
No takes yet. Share an insight, caveat, or question.
Agstam et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: